Mauna Kea Technologies closes $30M financing, renames U.S. subsidiary
Mauna Kea Technologies, an in vivo imaging developer, has closed a $30 million financing round led by U.S.-based Psilos Group, a healthcare private equity firm. France-based Seventure and existing investor Creadev also participated in this round of funding.
Paris-based Mauna Kea Technologies said it will use the proceeds to expand commercialization of its Cellvizio technology in the United States and Europe, as well as to advance additional clinical applications of the platform. David Eichler and Albert Waxman of Psilos will both join Mauna Kea Technologies' board of directors, according to Psilos.
Mauna Kea has also changed the name of its U.S. operations to Cellvizio Inc. to strengthen brand awareness.
"This financing will enable us to expand our U.S. presence and advance our clinical program to validate Cellvizio's utility in improving the diagnosis and treatment of disease found in the esophagus, colon, stomach, bile duct as well as the distal lungs," said Sacha Loiseau, PhD, founder, president and CEO of Mauna Kea Technologies.
Paris-based Mauna Kea Technologies said it will use the proceeds to expand commercialization of its Cellvizio technology in the United States and Europe, as well as to advance additional clinical applications of the platform. David Eichler and Albert Waxman of Psilos will both join Mauna Kea Technologies' board of directors, according to Psilos.
Mauna Kea has also changed the name of its U.S. operations to Cellvizio Inc. to strengthen brand awareness.
"This financing will enable us to expand our U.S. presence and advance our clinical program to validate Cellvizio's utility in improving the diagnosis and treatment of disease found in the esophagus, colon, stomach, bile duct as well as the distal lungs," said Sacha Loiseau, PhD, founder, president and CEO of Mauna Kea Technologies.